StemCell Therapy

July 22nd, 2020

12:00 PM - 1:00 PM ET

Whether you have been named power of attorney or have named someone to act as yours, it is crucial to understand the legal obligations and restrictions of power of attorney and living wills.

In this webinar, Whitney OReilly will provide tips and tricks for getting the most out of your power of attorney or living will, from making sure the appropriate parties are informed of their role to establishing a way of communicating the directives to hospitals, living facilities, and financial managers. She will highlight some of the key questions individuals should ask in the process of determining their power of attorney and creating living wills and will review the impact recent legislation has had on the power of attorney and living wills.

This webinar will feature a brief Q&A with Michael Snyder, who recently worked with the firm to manage the legal ramifications of sickness and death. Michael is the chair of the Department of Genetics and the director of the Center for Genomics and Personalized Medicine at Stanford University School of Medicine.

Read more:
[Webinar] The Dos and Donts of Power of Attorneys and Living Wills - July 22nd, 12:00 pm - 1:00 pm ET - JD Supra

MantHealth (NH) offers cancer molecular profiling solutions that enable personalization in a number of cancer treatments. This business, which has been lingering for a couple of years has received an important FDA approval which makes approval for Medicare and Medicaid use very likely. This, together with the sale of their Connected Care business has boosted the stock price significantly, but we think it's not too late to step on board.

The company is also is enabling a more integrated and data-driven healthcare solution through its two SaaS platforms, which are growing and account for most of the company's revenues to date.

These proven integration solutions are offered to an industry, which as they claim (and, dare we say, not without reason) suffers from a host of unnecessary complexity and inefficiencies, most notably:

Because of these inhibitions, the healthcare system is struggling to make the shift towards a more holistic, data-driven approach, the culmination of which is individualized medicine.

Personalized medicine is based on personalized data that is increasingly becoming available through advances in molecular medicine and real-time biometrics (remote monitoring devices and the like).

These solutions, like the company's own GPS business, generate a veritable deluge of data which, for a coordinated and individualized approach need to be collected, analyzed and distributed, and it's here where the company's SaaS solutions intervene and add value. We'll quickly introduce the company's solutions below.

From the 10-K:

GPS Cancer is a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing, providing oncologists with insights into the unique molecular signature of a patients cancer to inform personalized treatment strategies.

What GPS Cancer does is comparing the patient's whole genome/exome sequencing of a persons tumor sample with their normal sample in order to highlight molecular alterations that are specific to their tumor DNA.

These alterations are then subsequently confirmed by RNA sequencing. All this enables the matching of these alterations with drugs that might be effective against tumors containing the specific change. And these solutions are constantly fine-tuned by machine learning.

This is the company's blood based test that allows non-invasive profiling of tumors and monitoring quantitative response to treatment, from the 10-K:

Liquid GPS looks beyond cfDNA to cfRNA, which allows profiling and trending of actionable biomarkers that cannot be assessed through cfDNA alone. In addition to providing molecular insight into key guidelines-based biomarkers (e.g., EGFR, ALK, ROS1, KRAS), this powerful RNA-based approach enables a variety of capabilities and applications not typically available from a liquid biopsy test.

It is able to monitor targeted therapies, immunotherapy and chemotherapy responses.

This is the company's SaaS based decision support system which provides evidence-based clinical decision support for physicians who are threatened to be overwhelmed by today's rapid advancements in molecular and biometric medicine.

Eviti centralizes stuff like clinical content, treatment cost from Medicare reimbursements and treatment toxicity data. It has access to over 7600 clinical trials and 4000+ evidence-based treatment regimes.

NaviNet Open is a payer-provider workflow collaboration platform in order to increase efficiency, lower cost, improve provider satisfaction and enable communication between health plans and providers.

The company sold its Connected Care business for $47M in February to Masimo (MASI), exiting DCX, VCX, HBox and Shuttle Cable. The Connected Care business generated $1.2M in sales in Q1, a small part of overall revenue ($23M).

While operational performance has improved, the company hasn't been able to grow much in the past four years:

Data by YCharts

After the sale of its Connected Care business, the company has two revenue categories:

To date, the company's SaaS revenue generates most of its revenue but it does gain some revenue from sequencing and molecular analysis. However, last quarter saw a big decline to just $59K (down from $814K a year ago).

The stagnant revenue in part is just appearance as the company's SaaS business has been growing, from $60.7M in 2017 to $65.6M in 2018 to $72.8M in 2019, because the company de-emphasized its GPS business as costs were outweighing revenues. The company keeps on adding new customers (like here and here) to its SaaS businesses, a few were mentioned on the Q1CC.

The company keeps improving their products and adding new Eviti and NaviNet features.

For this business to take off, the wait is basically for a positive coverage determination from CMS, from the Q1CC:

we expect to continue to see minimal sequencing and molecular analysis revenue impact until we receive a positive coverage determination from CMS.

However, that event seems near, from the 10-K (our emphasis):

In the fourth quarter of 2019, we received FDA 510(K) authorization for Omics Core, the nations first FDA authorized whole exome tumor-normal in vitro diagnostic (IVD) that measures overall tumor mutational burden (TMB) in cancer tissue, completing a key step towards achieving Medicare coverage.

Which, together with the sale of the Connected Care business, explains the rally in the shares, from FinViz:

It's GPS business generated $2.55M in revenues in 2017, $3.13M in 2018 and $1.73M in 2019. Here too, apart from the FDA approval for Omics Core, there are other developments and improvements.

The company launched a new AI platform which can automatically distinguish sub-types lung cancer pathology and improves on that ability, from PR:

Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.

Accurately identifying and quantifying tumor-infiltrating white cells is extremely important for prognosis and treatment decisions in this era of personalized medicine, yet it currently requires manual review of whole slide images by medically trained pathologists, and incurs significant delays and cost, explains Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth.

And they are working on a similar solution for breast cancer. In principle, their TMB (tumor mutational burden) test capability is a generic capability with wide application scope, here is a description of the mechanics from company PR:

Omics Core reports a cancer patient's overall TMB by sequencing and comparing 19,396 protein-coding genes targeting 39 million base pairs of the human genome from a tumor sample and a normal sample, typically from blood or mucosal membrane. TMB indicates the sum of all acquired gene-coding mutations in a tumor genome and is increasingly used to predict response to therapy and identify tumors that could benefit from immunotherapy. In addition, the test reports somatic mutations in 468 cancer-relevant genes accurate to 2% allele frequency, to inform clinical decisions about patient treatment. "Tumor mutation burden ... is now recognized as a key biomarker across multiple tumor types," said Patrick Soon-Shiong, chairman and CEO of Nanthealth. "Studies have shown that immunotherapy treated with high TMB had better outcomes compared to those with low TMB."

And here is a description of a peer reviewed article how this improves targeting capabilities of treatments. It's the more general applicability of TMB and the FDA approval that shareholders are rejoicing.

According to management, two things stand out (PR, our emphasis):

Nanthealth is positioning its tumor-normal test as an advancement over competitors like Myriad Genetics Inc., Color Genomics Inc. and Invitae Corp., which have limited gene panels to look at hereditary risk. By sequencing the whole exome, "we have the ability to identify things that others are missing, and that's particularly critical for drug development," Sandeep Reddy, Nanthealth's chief medical officer, told BioWorld MedTech. "We know about maybe cancer risk, but what do we know about autism or Alzheimer's? By getting that information, that becomes transformative."

As described in that PR, the company's TMB test spots things that other solutions don't, resulting in a more personalized approach to what therapies might be more successful, and it has applicability beyond screening for cancers.

But from a financial point of view, things are also going pretty well.

Data by YCharts

GAAP margins have been trending up and gross margin was much better than a year ago (60% versus 49%), up on product mix (the shift towards its SaaS business).

Operating expenses declined from $20.2M in Q1 2019 to $16.8M in Q1 2020, but $1.1M of that decline is related to the sold Connected Care business.

While cash flow is still negative, there has been tremendous improvement in the last 2.5 years.

Data by YCharts

The net cash burn in Q1 was still around $5M, but this included various closing costs and other front-end loaded costs in relation to the sale of the Connected Care business.

And with that sale the balance sheet has improved a lot, with the company having $47.5M in cash on the books, although the company does have a substantial $95.3M in long-term debt, from the 10-Q:

Data by YCharts

The valuation has jumped along with the share price recently but we think it's still not excessive, it has been much higher in the past on a much more distant promise of monetizing their TMB solutions and in the meantime the company developed a successful SaaS business with their Eviti and NaviNet platforms.

With a backwards looking EV/S of 8X for a company with a unique product that is about to get monetized and a successful SaaS business is high, but not overly so. Analyst still expect EPS losses, $0.23 this year falling to -$0.18 next year, but the company doesn't burn much cash and has plenty of it.

While much is uncertain about the potential of the company's GPS business and the economics of it, the company does have unique capabilities that are likely to become important tools in fighting a number of cancers and the underlying capabilities seem to have wide applicability.

Add to that an attractive SaaS business a declining cash burn and the sale of its Connected Care business providing enough cash to keep the company going for the foreseeable future, and we think we still have an attractive proposition for shareholders, even if it looks like the shares might want to have to digest recent strong gains.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Excerpt from:
NantHealth Points To The Future Of Healthcare - Seeking Alpha

WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (IM Therapeutics), a leading innovator in the field of precision medicine for autoimmune disease, announced today that Mr. Tom Shea and Dr. Sarah Bird have joined its senior management team. Tom has joined as Chief Financial Officer and Chief Operating Officer (CFO/COO) and Sarah has been promoted to the position of Vice President, Clinical Development.

Tom has over 30 years of professional financial experience ranging from early-stage start-ups to commercial-stage and publicly traded companies. Most recently, Tom served as CFO of ImmusanT, a clinical stage therapeutic company in celiac disease and type 1 diabetes. He has served as CFO and has been involved in growth operations of a number of biotech companies, most notably Albireo Pharma, developing products for children with severe liver diseases, Tolerx, Inc., an immunology company focused on type 1 diabetes, and Cubist Pharmaceuticals, an infectious disease company. Over his career, Tom has led executive teams in raising significant capital and completing transactions for strategic collaborations. In addition, Tom has served as a Board Member of the New England chapter of JDRF, a world-renowned foundation devoted to the treatment and cure of T1D.

Sarah joined IM Therapeutics at its founding stage to help design and lead its clinical program development as Director, Clinical Development. She is a seasoned professional with over 20 years experience leading programs in basic, translational and clinical research. She has worked in academia, biotech and device industries in technologies from start-up to commercial stage. In her graduate and postdoctoral work at St Louis School of Medicine and later as a JDRF Fellow at the U. of Colorado, her research focused on autoimmune pathogenesis and potential therapeutic approaches. Sarah has led global programs at Medtronic, Gilead and pharmaceutical companies in both clinical and medical affairs managing cross-functional teams responsible for strategy, planning and execution. Sarah has led teams overseeing regulatory submissions and product approvals while actively raising physician and patient awareness in areas of unmet medical need.

I am excited to be working closely with Sarah and Tom as we advance our clinical programs and grow our pipeline, said Nandan Padukone, Ph.D., CEO of IM Therapeutics. Both Tom and Sarah have shown a great commitment to T1D and to bringing new drug programs in autoimmune disease to the clinic.

I find the underlying biology that genetically targets specific autoimmune pathogeneses to be fascinating and a unique opportunity to translate to clinical practice, said Dr. Bird. It is great to work with highly motivated people to impact patient care and personalized medicine, she added.

Mr. Shea further added, Ive had a long-standing interest in helping to progress companies working within the autoimmune space. I am pleased to be a part of this team and very hopeful of the targeted approach we are testing in T1D and other autoimmune diseases.

The Company recently announced that the first subject was dosed in a Phase 1 study of its lead drug, IMT-002, an oral drug designed as a selective HLA-DQ8 blocker for treatment of T1D and DQ8-related disease.

About IM Therapeutics

IM Therapeutics is a clinical stage company developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. In addition to its lead drug, IMT-002, directed at HLA-DQ8 activity for treatment of type 1 diabetes, the Company is building a broad pipeline of drugs against HLA targets such as DQ2, DR3 and DR4 in a range of autoimmune disorders including celiac disease. http://imtherapeutics.com/

Go here to read the rest:
IM Therapeutics Expands Management Team with Appointments of Tom Shea as CFO/COO and Dr. Sarah Bird as VP, Clinical Development - Business Wire

KING OF PRUSSIA, Pa., July 9, 2020 /PRNewswire/ --Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Awardfor coagulation research just ahead of the first ever virtual congress of the International Society on Thrombosis and Hemostasis (ISTH).

The annual global Professor Heimburger Awards program recognizes the clinical and/or preclinical research of emerging coagulation specialists who are driven to improve the care of patients with bleeding disorders.The program demonstrates the company's continuing promise to support pioneering research by providing a 20,000 (~$22,500) research grant annually, to each of five recipients. This year's recipients are:

"Our leadership in hemophilia and other bleeding disorders starts with innovative science and extends beyond what is happening in our own labs or product portfolio to advance research and patient care across the globe," said Antti Kourula, Vice President, Hematology Therapeutic Area, CSL Behring."We look forward to the exciting research the Heimburger Awards supports."

In addition, CSL Behring will highlight its continued commitment to scientific research and innovation by participating as a Gold level sponsor at ISTH 2020 Virtual Congress. During the Congress, CSL Behring will host two symposia and two product theaters, along with supporting eight posters. (Full abstracts may be reviewed at https://abstracts.isth.org/)

CSL Behring Supported Symposia & Product Theaters (Tuesday, July 14, 2020)

CSL Behring Supported Posters

About the CSL Behring Professor Heimburger AwardsProfessor Norbert Heimburger was an employee of CSL Behring for more than 30 years and devoted his work to blood coagulation. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization, a development that led CSL Behring to produce the world's first virus-inactivated factor VIII concentrate to treat patients with hemophilia. More information about the Professor Heimburger Awards, including application information for 2021 can be found at: https://www.cslbehring.com/r-and-d/awards-and-grants/professor-heimburger-award

About CSL BehringCSL Behringis a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, anddelivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

SOURCE CSL Behring

Link:
CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress - PRNewswire

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that is polarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

More:
Why are scientists trying to manufacture organs in space? - The Conversation US

The healthcare sector has started to utilize the patient engagement technology so that they can offer them with better treatments.

FREMONT, CA:Technology is continuously changing the face of the healthcare industry at an extremely high rate. If the new technologies are utilized effectively, healthcare organizations will meet the increasing demand and efficiently offer better service to the patients. Here are some of the trends related to patient engagement technology that the healthcare sector can follow.

Utilization of artificial intelligence (AI) and machine learning

Presently, the healthcare sector has also started to utilize technologies like machine learning and AI. However, it is expected that the utilization of these technologies will increase rapidly in the coming years and offer various benefits. Moreover, if the sector enhances their research and clinical trials' efficiency by developing new tools, it will help them to fulfill the demands of the patients and even make the process cost-efficient.

The opinion about technologies like chatbots is also changing because the patients can directly book their appointments or solve their queries related to medications. Moreover, Conversational AI will also help the patients and the healthcare providers to converse among each other through written or spoken language.

Advancement of personalized treatment using predictive medicine

Presently various new applications are coming up that are prioritizing predictive healthcare so that the patients get introduced to more effective treatments. Wearables are a useful technology that can be used for capturing the data for treatment purposes. Therefore, the healthcare sector is applying wearable technologies to create opportunities for organizations to offer personalized treatment to the patients.

Furthermore, the data that has been collected from the smartwatches and trackers will allow the healthcare facilities to get a better idea and start treatment of the issues in advance before it starts showing symptoms in the patients. The doctors can also prescribe the medications accurately due to precision medicine as it is data driven.

The continuous growth of digital platforms

As the consumers want a better and sophisticated service so that they can manage their necessities, the popularity of the all-in-one platform is increasing. In the healthcare sector, the consumers are also expecting a user-friendly and customer-first digital experience, and this all-in-one platform can offer them with it.

However, in the healthcare sector, it is necessary to apply the new technologies in their present business model and IT infrastructure to offer better treatment to their patients.

See also:Top Machine Learning Companies

See original here:
How Patient Engagement Technology is Transforming the Healthcare... - Healthcare Tech Outlook

Genomics Market report highlights CAGR value fluctuations during the forecast period of 2020-2025 for the market. The report presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. A market research analysis and estimations carried out in this Genomics report aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Furthermore, market research report also provides a watchful investigation of the current state of the market which covers several market dynamics.

Businesses can accomplish unparalleled and comprehensive insights along with the best acquaintance of the emerging market opportunities with this Genomics market research report. This report is structured with the meticulous efforts of innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry experts, and forecasters. By understanding clients requirements precisely, this report brings together business and product information for the sustainable growth in the market. Two of the major tools of market analysis employed are SWOT analysis and Porters Five Forces Analysis. The Genomics report is generated with a nice combination of advanced industry insights, practical solutions, talent solutions and the use of latest technology which gives an excellent user experience.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPTE100000730/

MARKET INTRODUCTION

The global genomics market is expected to reach US$ 32,995.3 Mn in 2025 from US$ 14,728.6 in 2017. The market is estimated to grow with a CAGR of 10.8% from 2018-2025.

Genomics market is segmented by technology, product & services, application and end user. Global genomics market, based on technology was segmented into sequencing, microarray, PCR, nucleic acid extraction and purification, and others. Global genomics market, based on the product & services was segmented into instruments/systems, consumables, and services. The genomics market, based on application was segmented into diagnostics, drug discovery & development, precision/personalized medicine, agriculture & animal research and others. The genomics market is bifurcated on basis of end user such research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users.

Key Competitors In Market are

The top 10 industry players operating in the market of genomics across the globe includes Thermo Fisher Scientific Inc., Illumina Inc., and Eurofins, Qiagen, Agilent Technologies, BGI, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Danaher, and GE Healthcare. For instance, in October 2017, MGI Tech, a subsidiary corporation of BGI, launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200 in Shenzhen, China. MGI also launched a modular NGS workstation, MGIFLP along with other products. And the launch expanded the business of the company in global genomics market.

TOC of Market Report Contains:

MARKET SCOPE

The objective of the study is to describe, define, and forecast the genomics market by technology, product & services, application, end user and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall market.

Market segmentation:

Genomics Market to 2025 Global Analysis and Forecasts by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, and Others), Product & Service (Instruments/Systems, Consumables, and Services), Application (Diagnostics, Drug Discovery and Development, Precision/Personalized Medicine, Agriculture & Animal Research, and Others) End User (Research Centers, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Click to buy full report with all description:https://www.theinsightpartners.com/buy/TIPTE100000730/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read more:
Genomics Market 2020 Insight On The Analysis By Essential Factors And Trends In Industry By 2025 - 3rd Watch News

Post by Lisa Carroll, Canadian Public Sector Lead, Microsoft Canada

As the COVID-19 pandemic unfolded earlier this year, healthcareprovidersacross the country found themselves like so many other organizations having to urgently reinvent ways to operate, provide patient care, manage supply chains and deploy resources, with many of the usual ways of doing things suddenly off the table.With every second counting,the industryquicklyrealizedthat the immediate implementation andredeploymentof valuable resources wasanimperative.

It hasnt been easy, butamidst the crisisand uncertainty, we have continued to persevere.I amtrulyamazed at the incredibletransformationour healthcaresystemhasimplemented in such a short period of time.Healthcare providersquickly pivoted to newways of operating, while also coming together as a community todevelopnew solutionsforsafe and securetesting toprotect the health and wellbeing of our Citizens andsupporting the initiation ofthereopening our economy.

Microsoft has been working closely withpartnersand customersthroughout the pandemicto solve these big challenges by connecting health data and systems in the cloud, making health work better for patients and providers, and advancing precision medicine.Akey priority for us is providingthese organizationswith the peaceof mind to remainconfidentthattheir data is beingprocessed bytrustedMicrosoft platformsthat aresecure and compliant by designmeetingmore than70industry-widecertifications.Recognizing that thehealthcare sector is particularly vulnerable tocyber-attacksduring times of crisis, Microsofthas also recentlyimplementedanintensified monitoring and takedown ofpotentialthreatswith anemphasis on protecting critical services,such ashospitals.

I wanted to take a moment to pause and recognize the resilience and ingenuity of a smallsamplingof the many organizations who areresponding and protectingour communities across Canada:

POWERING THE HEART OF VIRTUAL CARE

POWERING INSIGHTS FOR BETTER PATIENT OUTCOMES

ACCELERATING HEALTHCARE DELIVERY

There is something to be said about hownecessityand emergencyoften drive innovation, andwe are especially proud to becollaboratingwith Citizen Care Pod Corporation,WZMH Architects, PCL Construction and Insight Enterpriseson a new initiative todeveloped with the intent torevolutionizetheaccessibilityand safety of COVID-19 testing.The Citizen Care Pod is a customizable unit outfitted with the capabilities to enable turnkey mobile COVID-19 testing in high-traffic business environments and communities with the goal to expedite testing, screening, and eventually vaccination on mass scale.

Utilizing modular construction methods, PCL Construction is manufacturing and assembling the pods by retrofitting shipping containers with customizable options to support rapid delivery and installation toany site, including high-traffic or remote locations.Eachpodis equipped with a suite of intelligent, customizable technologies powered by Microsofts trusted Azure and AI platform,which support a safe and secure testing environment for patients and front-linehealthcareworkers.

CANADIANS ARESTRONGER TOGETHER

Each passing day of this pandemic bringsnew challenges,butitsbeenincredible to see howgovernments and healthcare organizations across the countryarequickly reinventingways to operateasmany of the changes put in place today will help medical professionals deliver personalized care to Canadians in new, innovative ways in the post-COVID world.

We are proud to be part of new solutionsand new partnerships as we join together in our common cause.As the saying goes, it takes a village and at Microsoft we are committed to being there for all of our customers and partners to weather this storm together.

To learn more about Microsoft solutions that can help in the fight against COVID-19, visitaka.ms/healthcareincanada

More here:
Supporting Canada's Healthcare Industry with Trusted Technology in Response to COVID-19 - Microsoft

Ripple Science Logo

ANN ARBOR, Mich. (PRWEB) July 09, 2020

Ripple Science today announced their partnership with Lakeside Life Science, a diagnostic research organization that is performing a clinical study to determine antibodies using Medsentials COVID-19 IgG/IGM Rapid Test Cassette. With 11.6 Million cases and over 500,000 deaths worldwide, the public health crisis that is COVID-19 has accelerated organizations to adopt technology like Ripple, which shorten time-to-market for biopharma solutions.

Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts, leading to valuable time and cost savings. Medsentials test is already available for high-complexity CLIA certified labs. Lakesides study will be validating the test in a clinical setting. Paul Allard, COO of Lakeside Life Science, explained how Ripple helps with a very short timeline: Ripple is streamlining the whole clinical study process for us. Our timeline for this study is incredibly short. Normally we need four to six months for study start up and 18 months to enroll patients. Our goal is to complete this entire study under a month and a half.

Allard anticipates a follow-on study to determine how long a person has the antibodies. Lakeside, an expert in testing validation, has confirmed that Medsentials IgM/IgG antibody test outperform antibody tests from well-known industry healthcare providers. Allard said, In moving to a long-term study, we want high confidence in our antibody testing solution and are delighted at Medsentials results and how easy the tests are to use.

Lakeside is using Ripple to quickly recruit and track patients from small, underserved community centers that dont have access to standard testing or the tools to manage clinical studies. Patients from these small centers can benefit from access to testing and are more representative of the general population.

Clinical studies are known for their complex nature beginning with recruiting patients to continual patient engagement, especially for follow-up months after the study commences. Chiao-ih Hui, COO for Medsential, is pleased that many of the study complexities are being removed. I love that Ripple is making this highly involved and complex clinical process easier and streamlined. This will accelerate and provide a model for getting our solution to point-of-care settings and to vulnerable populations who have the most need for these solutions.

President and CEO of Ripple Science, Peter Falzon commented, With COVID-19, the way we conduct clinical trials has changed and there is a heightened sense of urgency. The team at Ripple Science is dedicated to enabling clinical research teams to work remotely and adopt virtual research methods, while boosting recruitment and retention.

About Lakeside Life Science:Lakeside Life Science was founded in January of 2015, by W. Jeffrey and Paul Allard to bring patients and communities together to advance personalized medicine through the research and development of novel diagnostic tests. Lakeside provides the resources for their clients to bring their assays from invention to FDA clearance/approval, while putting patient needs first.

About Medsential: Medsential LLC is a US FDA registered company that develops, manufactures, and distributes a broad range of medical products to customers. Established in 2005, Medsential is an ISO certified medical device company with the capabilities to manufacture and assemble a broad range of products. Medsential has an extensive distribution channel, salesforce, engineering platform, and production team to bring quality products to global markets.

About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up. Ripple Sciences flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.

To learn more, please visit: https://www.ripplescience.com

Share article on social media or email:

Read more:
Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential's Point-of-Care COVID-19 Antibody Test...

The Global Collagen Market for Regenerative Medicine is projected to reach $679.9 Million, at a CAGR of 10.1% during the forecast period. The GlobalGelatin Market for Regenerative Medicine is projected reach $94.9 Million, at a CAGR of 7.8% during the forecast period.

According to the new market research report "Collagen and Gelatin Market for Regenerative Medicine (by Source (Bovine, Porcine, Marine), Application (Wound Care, Orthopedic, Cardiovascular)), Value and Volume Analysis - Global Forecast" published by MarketsandMarkets

Major Market Growth Drivers:

Browse155 Market Data Tables and48 Figures spread through177 Pages and in-depth TOC -Request Research Sample Pages:www.marketsandmarkets.com/requestd=95663122

Market Segmentation in Depth:

The bovine collagen segment accounted for the largest share of the market

By source, the global collagen market for regenerative medicine has been segmented into bovine collagen, porcine collagen, marine collagen, and other sources. The bovine collagen segment is expected to command the largest share of the global collagen market for regenerative medicine.

The large share of this segment is attributed to the lower cost and extensive availability of bovine collagen.

The orthopedic applications accounted for the largest share of the global collagenmarket for regenerative medicine

On the basis of application, the global collagen market for regenerative medicine has been segmented into orthopedic, wound care, cardiovascular, and other applications. The orthopedic applications segment is expected to command the largest share of the global collagen market for regenerative medicine.

The large share of this segment can primarily be attributed to the high prevalence of osteoporosis.

Download PDF Brochure:www.marketsandmarkets.com/pdfdownd=95663122

Geographical Regions Mapped in Report:

North America is expected to account for the largest share of the collagen market for regenerative medicine. The high incidence of periodontitis, increasing prevalence of heart diseases and diabetes in the U.S., and growing number of research studies in Canada are the major factors supporting the growth of this market.

The Asia-Pacific region is projected to register the highest growth rate during the forecast period.

Major Key Players Mapped in Research Report:

The major players operating in the global collagen market for regenerative medicine include Integra LifeSciences Holding Corporation (U.S.), Collagen Matrix, Inc. (U.S.), Collagen Solutions plc (U.K.), Royal DSM (Netherlands), Vornia Biomaterials, Ltd.(Ireland), SYMATESE (France), and NuCollagen, LLC. (U.S.).

The major players operating in the global gelatin market for regenerative medicine include GELITA AG (Germany), Nitta Gelatin, Inc. (Japan), and PB Gelatin (Belgium).

This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:
Explore the Collagen and Gelatin Market for Regenerative Medicine | growth drivers, segmentation & geographical analysis - WhaTech Technology and...

Latest update on Orthopedic Regenerative Medicine Market Analysis report published with an extensive market research, Orthopedic Regenerative Medicine market growth. This report is highly predictive as it holds the overall market analysis of topmost companies into the Orthopedic Regenerative Medicine industry. With the classified Orthopedic Regenerative Medicine market research based on various growing regions this report provide leading players portfolio along with sales, growth, market share and so on.

In 2018, the consumables segment held a largest market share of the Orthopedic Regenerative Medicine market, by product. The consumables segment is also expected to dominate its market share in 2027 as the consumables are widely used for several times. The rising number of research and developments and clinical activities are likely to grow market. The segment is also anticipated to witness the fastest growth rate during the forecast period, 2020 to 2027.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/3566

Orthopedic Regenerative MedicineMarket Competitive Landscape

Key players operating in theOrthopedic Regenerative Medicine market include Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Orthopedic Regenerative Medicine Market Regional Analysis

For comprehensive understanding of market dynamics, the Global Orthopedic Regenerative Medicine Market is analyzed across key geographies namely North America, Europe, China, Japan, Southeast Asia, India, Central & South America. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

What will you get in this report?

An exhaustive analysis of the global Orthopedic Regenerative Medicine market with detailed studies on different topics that will help key players to create effective development strategies and strengthen a strong position in the Orthopedic Regenerative Medicine industry.

It gives a complete mapping of the behaviors of Orthopedic Regenerative Medicine market contributors and the vendor landscape. Existing companies could use the report to prepare themselves well to face future market challenges and strongly compete in the global Orthopedic Regenerative Medicine market.

Also, the analysts have provided a thorough assessment of the impact of these strategies on Orthopedic Regenerative Medicine market growth and competition and many more

A competitive portfolio of Orthopedic Regenerative Medicine market in the different regions including their growth factors, pitfall challenges, investment structure, advancement in all aspects, customer base etc.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/3566

A Pin-point overview of TOC of Orthopedic Regenerative Medicine Market are:

Overview and Scope of Orthopedic Regenerative Medicine Market

Orthopedic Regenerative Medicine Market Insights

Industry analysis Porters Five Force

Company Market Share Analysis

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @https://www.coherentmarketinsights.com/insight/request-discount/3566

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahEmail:[emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

Original post:
Impact of the COVID-19 on Orthopedic Regenerative Medicine Market is Growing Rapidly by 2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika...

The Global Stem Cells Group (GSCG) a world leader in Regenerative Medicine Technologies has signed an agreement with South Korean-based Rokit Healthcare, an esteemed bioprinter manufacturer that is committed to advancing the field of regenerative medicine and bettering the quality of life of people around the world.

The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Growth factors are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an organ regenerator it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.

The process of 3D bioprinting human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in regenerative medicine research and tissue engineering is mimicking the micro and macro environment of human tissues. In response to this challenge, advances in additive manufacturing have inspired scientists in Korea to develop novel bioprinting technology, for human tissues and organs.

With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing and Global Stem Cells Group, in an effort make this revolutionary technology available to patients, has forged an agreement with Rokit Healthcare to promote, and distribute the companys technology in Latin America-

The Invivo 4D Printer is Rokit Healthcares flagship product, and it is one that revolutionizes the application of regenerative medicine and growth factor-based therapies. creating a solution for personalized and improved patient care. By leveraging a combination of 3D and bioprinting technologies, it can better distribute a patients autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.

Were extremely excited about this new opportunity and look forward to working with Rokit, Says Benito Novas, CEO of the Global Stem Cells Group, The Invivo 4D Printer is in a position to turn the practice of regenerative medicine onto its head, and we are planning on creating a training center in Cancun, Mexico exclusively to showcase and instruct other physicians in this cutting-edge technology,

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCGs affiliate companies provide medical practitioners with a one-stop hub for regenerative medicine solutions that adhere to the highest medical standards.

About ROKIT :

ROKIT Healthcare is a global healthcare company that is committed to providing an effective and autologous organ regeneration platform. In order to undertake this daunting task, the company uses proprietary biofabrication technologies that show promise in treating several types of diseases in the field of regenerative medicine. Through the proliferation of 4D bioprinting technology, autologous stem cell technologies, ROKIT Healthcare believes that supplying an avenue for organ regeneration will drastically change the way that everyday people trust and manage their own body.

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCGs affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Read more from the original source:
Global Stem Cells Group has Announced an Agreement with Rokit Healthcare - PRUnderground

Can a pill provide the same cognitive benefits as exercise? [University of California, San Francisco]

The results of research in mice suggest that a little-studied liver enzyme called Gpld1 may be responsible for the well-known benefits of exercise on the aging brain, and that its regenerative effects may be transferrable directly from one animal to another. The studies, headed by scientists at the University of California, San Francisco (UCSF), Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, showed that when aged, sedentary mice received plasma transfusions from regularly exercising mice, they gained the same beneficial neurological effects without having to hit the running wheel themselves.

The findings could feasibly lead to new therapies that confer the neuroprotective effects of physical activity on people who cant exercise due to physical limitations. If there were a drug that produced the same brain benefits as exercise, everyone would be taking it, said Saul Villeda, PhD, a UCSF assistant professor in the departments of anatomy and of physical therapy and rehabilitation science. Now our study suggests that at least some of these benefits might one day be available in pill form. Research lead Villeda is senior author of the teams published paper in Science, which is titled, Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain.

Exercise is one of the best-studied and most powerful ways of protecting the brain from age-related cognitive decline. Exercise has been shown to improve cognition in individuals at risk of neurodegenerative diseases such as Alzheimers disease (AD) and frontotemporal dementia, even for individuals who carry rare gene variants that inevitably lead to dementia.

In the context of dementia-related neurodegenerative diseases, exercise is correlated with reduced risk for cognitive decline in the elderly, improves cognition in populations at risk for AD, and is associated with better neurobehavioral outcomes even in autosomal dominant AD, the scientists wrote. However, not everyone is able to exercise regularly as they get older, perhaps due to physical limitations or other disabilities. Despite the evident benefit of exercise, its application is hindered in the elderly, as physical frailty or poor health can decrease a persons ability or willingness to exercise, the authors continued. Researchers have long searched for strategies that could confer some of the same neurological benefits of exercise to people with low physical activity levels.

Villedas lab has previously shown thatbiological factorspresent in the blood of young mice can rejuvenate theaging mouse brain, and conversely, factors in the blood of older mice can bring on premature age-related cognitive decline in young mice. transfer of blood from young animals, either by heterochronic parabiosis (in which young and old circulatory systems are joined) or by administration of young blood plasma, improves regenerative capacity and cognition in aged mice, the authors noted.

These previous results led Alana Horowitz, a graduate student in the Villeda lab, and postdoctoral researcher Xuelai Fan, PhD, to look for blood-borne factors that might also confer the benefits of exercise, which is known to rejuvenate the aging brain in a similar fashion to that seen in the labs young blood experiments. Given parallels between the effects of exercise and young blood, we tested whether exercise-induced circulating blood factors could confer the beneficial effects of exercise on regenerative and cognitive function in the aged brain, the scientists continued.

To do this Horowitz and Fan took blood from aged mice who had exercised regularly for seven weeks and administered it to sedentary aged mice. They found that four weeks of this treatment produced dramatic improvements in learning and memory in the older mice, similar to that seen in the mice who had exercised regularly. When they examined the animals brains, they found evidence of enhanced production of new neurons in the hippocampus, a well-documented proxy for the rejuvenating benefits of exercise.

To discover what specific biological factors in the blood might be behind these effects, Horowitz, Fan, and colleagues measured the amounts of different soluble proteins in the blood of active versus sedentary mice. They identified 30 candidate proteins, 19 of which, to their surprise, were predominantly derived from the liver and many of which had previously been linked to functions in controlling the bodys metabolism. Two of these proteins, Gpld1 and Pon1m stood out as particularly important for metabolic processes, and the researchers chose to study Gpld1 in more detail because few previous studies had investigated its function. We figured that if the protein had already been investigated thoroughly, someone would have stumbled upon this effect, Villeda said. I like to sayif youre going to take a risk by exploring something new, you might as well go big!

The team found that Gpld1 increased in the blood circulation of mice following exercise, and that levels of the protein correlated closely with improvements in the animals cognitive performance. Analysis of human data collected as part of the UCSF Memory and Aging Centers Hillblom Aging Network study also found elevated blood levels in healthy, active elderly adults, compared with levels in less active elders. These data identify Gpld1 as an exercise-induced circulating blood factor in aged mice and humans with potential relevance to cognitive function in mice, they wrote.

To test whether Gpld1 itself could drive the observed benefits of exercise, the researchers then engineered mice to overexpress Gpld1 in the liver, and evaluated the animals performance in multiple tests that measure various aspects of cognition and memory. To their amazement, three weeks of the treatment produced effects similar to six weeks of regular exercise, and also generated dramatic increases in new neuron growth in the hippocampus. Together, these data indicate that selectively increasing liver-derived systemic concentrations of Gpld1 is sufficient to improve adult neurogenesis and cognitive function in the aged hippocampus, the scientists stated.

To be honest, I didnt expect to succeed in finding a single molecule that could account for so much of the benefits of exercise on the brain, Villeda noted. It seemed more likely that exercise would exert many small, subtle effects that add up to a large benefit, but which would be hard to isolate. When I saw these data, I was completely floored Through this protein, the liver is responding to physical activity and telling the old brain to get young. Further laboratory experiments have shown that Gpld1 produced by the liver does not pass through the blood-brain barrier. Instead, the protein appears to exert its effects on the brain via pathways that reduce inflammation and blood coagulation throughout the body. Both blood coagulation and inflammation are known to be elevated with age and have been linked to dementia and age-related cognitive decline.

This is a remarkable example of liver-to-brain communication that, to the best of our knowledge, no one knew existed, Villeda continued. It makes me wonder what else we have been missing in neuroscience by largely ignoring the dramatic effects other organs might have on the brain, and vice versa.

The findings could have more broad-ranging implications, the authors suggested. Cumulatively, our data show that beneficial effects of exercise on the aged brain can be transferred through administration of blood components Given that transfer of young blood simultaneously elicits central and peripheral enhancements in regenerative capacity in aged mice, our data raise the possibility that the beneficial effects of exercise could be promoted broadly across tissues through circulating blood factors.

The Villeda lab is now working to better understand precisely how Gpld1 interacts with other biochemical signaling systems to produce its brain-boosting effects. The hope is to identify specific targets for therapeutics that could one day confer many of the protective benefits of exercise for the aging brain.

Go here to see the original:
Could Some of the Benefits of Exercise on the Brain be Captured in a Pill? - Genetic Engineering & Biotechnology News

NEW YORK, July 7, 2020 /PRNewswire/ --Americord Registry, the nation's fastest-growing cord blood bank, announced today that it will be distributing tens of thousands of additional surgical face masks, as well as informational pieces about COVID-19,to obstetric practitioners and their patients nationwide amid the ongoing pandemic.

The announcement comes as some states are seeing a resurgence in infection rates. CHF Industries partnered with Americord to make the additional face masks available. "I heard about what Americord was doing and reached out to Martin [Smithmyer, Americord CEO] through our YPO chapters to see if we could assist," said Spencer Foley, CEO of CHF Industries.

The masks and informational pieces will be distributed to practitioners as well as office staff who are on the front lines, beginning the week of July 6th.

"We began donating masks to obstetricians in April when we saw an opportunity to help thousands of offices facing critical shortages of PPE, and are so happy we can continue to provide not only protective equipment, but also assist in helping provide answers to questions pregnant patients are asking about COVID-19 and how it may impact their pregnancies," Smithmyer added.

Americord Registry continues to provide its clients with best-in-industry solutions to the preservation of umbilical cord stem cells and tissues. The COVID-19 pandemic has highlighted another potential use of mesenchymal stem cells found in cord tissue as a potential treatment. Working with researchers around the country to advance the use of stem cells in regenerative medicine is a strategic objective of the company.

For more information please contact:

Jean RolandOutreach Manager, Americord Registry646.768.8432[emailprotected]

SOURCE Americord Registry

americordblood.com

Read more:
Americord Registry Announces Distribution of Additional Thousands of Masks Amid COVID-19 Resurgence - PRNewswire

By: Express News Service | Surat | Published: July 10, 2020 8:50:59 pm He was immediately taken to the NCH trauma centre where doctors declared him dead on arrival.

A 56-year-old executive engineer fell down from the tenth floor of the Stem Cell Hospital at New Civil Hospital (NCH) in Surat, where work to convert the facility into a dedicated Covid hospital is in progress. It has not been established whether the engineer committed suicide or accidentally fell down, police said.

Jashwant Shihora (56), a resident of Parle Point area in Surat, who worked as an executive engineer at the electrical department of Project Implementation Unit, reached the Stem Cell Hospital at NCH on Friday morning, to conduct a routine check.

According to police sources, Jashwant had gone to the tenth floor alone and fell down under mysterious circumstances. The other labourers immediately gathered at the spot even as Jashwants head was profusely bleeding. He was immediately taken to the NCH trauma centre where doctors declared him dead on arrival.

Surat district collectorate officials along with Khatodara police had also reached the spot. The statements of a few engineers working there were taken and the police began a probe.

Khatodara police inspector KB Zala said, We have registered a case of accidental death and started a probe, It is difficult to say at this moment whether he had committed suicide or accidentally fallen down. He was alone at the topmost floor of the building. We are looking into all aspects.

In view of the rise in Covid-19 cases in Surat, Gujarat Chief Minister Vijay Rupani had arrived in the city on July 4 to take stock of the situation. While addressing media persons at the district collectors office, he had said, The Stem Cell Hospital building (600 beds) which at present is not being used, as some work is pending there, will be converted to a Covid hospital within a week. The Kidney Hospital building (700 beds) will also be converted into a dedicated Covid hospital.

Both buildings are located in the premises of the NCH campus and only their external structure has been made so far. Following the CMs announcement, district administrative officials had given contracts to three agencies to develop both hospitals.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Ahmedabad News, download Indian Express App.

The Indian Express (P) Ltd

Read the rest here:
Surat: Engineer falls to death from tenth floor of under construction Covid hospital - The Indian Express

Four more biotechs are raising their offers in an already record year for biotech IPOs.

Softbank-backed Relay Therapeutics scratched out its original $200 million filing and proposed a $250 million raise that would make them a $1.5 billion company. CAR-T developer Poseida Therapeutics bumped itself up $74 million to $224 million. Off-the-shelf cell therapy startup Nkarta upped from $150 million to $215 million and then priced even higher, at $252 million. Frances Inventiva did its own modest reset, raising its bar from $102 million to $108 million.

Poseida, Nkarta and Inventiva priced today. Relay will price next week.

Barring a surprise flop, the latest flurry of raisesmeans there will be 13 $200 million-plus biotech IPOs in 2020 before August. By contrast, all of 2019 saw two biotechs pass that mark; 2018 saw 7 do so.

The run of eye-catching deals began in the first days of April when, after a pair of pandemic-driven stock market crashes, the small and little-known biotech Zentalis managed to score $165 million in a public offering. At the time, Nasdaqs Jordan Saxe told Bloomberghe expected biotech to open the IPO market back up, with its investors more focused on the long term than a short term that had the potential to be brutal. He predicted 30-35 IPOs for $3.5 billion and a series of blank check companies, a pair of predictions that have since looked prescient.

Its not just private companies that are getting in on the action. Public biotechs, too, have put out for large raises. This week alone Vir Biotechnology offered $300 million in a secondary offering, Revolution Medicines offered $156 million and Akero Therapeutics offered $188.2 million.

The buzz has allowed, among other things, very early stage companies to attract significant interest, including a single week in June when three preclinical biotechs raised over $200 million in a single week.

That trend has continued into this week. Nkarta, focused on natural killer cell therapies, has yet to bring a candidate into the clinic, although they plan to do so later this year. Relay Therapeutics, focused on solid tumors, only started their first trial earlier this year.

Poseida and Inventiva, though, are further along. With backing from Novartis, Poseidas BCMA CAR-T is already in Phase II and, earlier this year, they started recruiting for a Phase I with another CAR-T therapy. Inventiva is in Phase II for a NASH drug and a mucopolysaccharidosis type VI drug.

Read the original:
Another four biotechs scratch out the first number and ask for more as IPO boom continues - Endpoints News

The 2020 award celebrates outstanding research in rare diseases Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK) and the New York Academy of Sciences announced today the Winners of the third annual Innovators in Science Award for their excellence in and commitment to innovative science that has significantly advanced the field of rare disease research.

Each Winner receives a prize of US $200,000.

This press release features multimedia.

View the full release here: https://www.

businesswire.

com/news/home/20200708005039/en/The 2020 Winner of the Senior Scientist Award is Adrian R.

Krainer, Ph.

D.

, St.

Giles Foundation Professor at Cold Spring Harbor Laboratory.

Prof.

Krainer is recognized for his outstanding research on the mechanisms and control of RNA splicing, a step in the normal process by which genetic information in DNA is converted into proteins.

Prof.

Krainer studies splicing defects in patients with spinal muscular atrophy (SMA), a devastating, inherited pediatric neuromuscular disorder caused by loss of motor neurons, resulting in progressive muscle atrophy and eventually, death.

Prof.

Krainers work culminated notably in the development of the first drug to be approved by global regulatory bodies that can delay and even prevent the onset of an inherited neurodegenerative disorder.

Collectively, rare diseases affect millions of families worldwide, who urgently need and deserve our help.

Im extremely honored to receive this recognition for research that my lab and our collaborators carried out to develop the first approved medicine for SMA, said Prof.

Krainer.

As basic researchers, we are driven by curiosity and get to experience the thrill of discovery; but when the fruits of our research can actually improve patients lives, everything else pales in comparison.

The 2020 Winner of the Early-Career Scientist Award is Jeong Ho Lee, M.

D.

, Ph.

D, Associate Professor, Korea Advanced Institute of Science and Technology (KAIST).

Prof.

Lee is recognized for his research investigating genetic mutations in stem cells in the brain that result in rare developmental brain disorders.

He was the first to identify the causes of intractable epilepsies and has identified the genes responsible for several developmental brain disorders, including focal cortical dysplasias, Joubert syndromea disorder characterized by an underdevelopment of the brainstemand hemimegalencephaly, which is the abnormal enlargement of one side of the brain.

Prof.

Lee also is the Director of the National Creative Research Initiative Center for Brain Somatic Mutations, and Co-founder and Chief Technology Officer of SoVarGen, a biopharmaceutical company aiming to discover novel therapeutics and diagnosis for intractable central nervous system (CNS) diseases caused by low-level somatic mutation.

It is a great honor to be recognized by a jury of such globally respected scientists whom I greatly admire, said Prof.

Lee.

More importantly, this award validates research into brain somatic mutations as an important area of exploration to help patients suffering from devastating and untreatable neurological disorders.

The 2020 Winners will be honored at the virtual Innovators in Science Award Ceremony and Symposium in October 2020.

This event provides an opportunity to engage with leading researchers, clinicians and prominent industry stakeholders from around the world about the latest breakthroughs in the scientific understanding and clinical treatment of genetic, nervous system, metabolic, autoimmune and cardiovascular rare diseases.

At Takeda, patients are our North Star and those with rare diseases are often underserved when it comes to the discovery and development of transformative medicines, said Andrew Plump, M.

D.

, Ph.

D.

, President, Research & Development at Takeda.

Insights from the ground-breaking research of scientists like Prof.

Krainer and Prof.

Lee can lead to pioneering approaches and the development of novel medicines that have the potential to change patients lives.

Thats why we are proud to join with the New York Academy of Sciences to broadly share and champion their workand hopefully propel this promising science forward.

Connecting science with the world to help address some of societys most pressing challenges is central to our mission, said Nicholas Dirks, Ph.

D.

, President and CEO, the New York Academy of Sciences.

In this third year of the Innovators in Science Award we are privileged to recognize two scientific leaders working to unlock the power of the genome to bring innovations that address the urgent needs of patients worldwide affected by rare diseases.

About the Innovators in Science AwardThe Innovators in Science Award grants two prizes of US $200,000 each year: one to an Early-Career Scientist and the other to a well-established Senior Scientist who have distinguished themselves for the creative thinking and impact of their research.

The Innovators in Science Award is a limited submission competition in which research universities, academic institutions, government or non-profit institutions, or equivalent from around the globe with a well-established record of scientific excellence are invited to nominate their most promising Early-Career Scientists and their most outstanding Senior Scientists working in one of four selected therapeutic fields of neuroscience, gastroenterology, oncology, and regenerative medicine.

Prize Winners are determined by a panel of judges, independently selected by the New York Academy of Sciences, with expertise in these disciplines.

The New York Academy of Sciences administers the Award in partnership with Takeda.

For more information please visit the Innovators in Science Award website.

About Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI).

We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.

Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.

takeda.

com.

About the New York Academy of SciencesThe New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide.

With more than 20,000 members in 100 countries around the world, the Academy is creating a global community of science for the benefit of humanity.

The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions and increase the number of scientifically informed individuals in society at large.

Please visit us online at www.

nyas.

org.

.

Read the rest here:
Takeda and the New York Academy of Sciences Announce 2020 Innovators in Science Award Winners - BusinessGhana

Polygenic risk scores, which evaluate disease risk based on DNA variants, have previously been based almost entirely on patients who had European ancestry.

The project, Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network, will build upon work of the existing eMERGE Network, and help these institutions recruit a higher percentage of patients from diverse ethnic backgrounds. The goal is to serve patients who are typically underrepresented in clinical trials or who typically have poor clinical outcomes.

NHGRI funds eMERGE, which brings together DNA biorepositories with electronic health record (EHR) systems to allow high-throughput genetic research to advance personalized medicine. While much of this kind of work is associated with cancer research, eMERGE and the grants awarded in the new round of funding will work to advance protocols that will determine care models for diabetes and cardiovascular disease and determine who is at risk for Alzheimer disease.

The challenge of bringing diversity to clinical trials has been well-documented in the scientific literature in recent years. A 2016 workshopat the European Society of Human Genetics explored the need to address disparities by engaging communities that been historically underrepresented in genomics research; without data from these populations, interpreting genetic testing results would be difficult when these patients sought care, and pathways based on clinical trials might not produce the same outcomes in these populations.

Where the Money Goes

In addition to the $61 million to the 10 sites, $13.4 million will go to the eMERGE Network Coordinating Center at Vanderbilt University.

The 10 sites will be in 2 categories. The first group, to include Mayo Clinic, Rochester,Minnesota; Vanderbilt University Medical Center, Nashville, Tennessee; Brigham and Womens Hospital, Boston; and Northwestern University, Chicago, will seek 10,000 patients, of which at least 35% should be from underrepresented groups.

The second set of locations, called enhanced diversity clinical sites, will seek 15,000 patients, of which 75% must be from diverse groups. These are the University of Alabama, Birmingham; Icahn School of Medicine at Mount Sinai, New York City; Cincinnati Children'sHospital Medical Center; Columbia University, New York City; Childrens Hospital of Philadelphia; and University of Washington Medical Center, Seattle.

Officials for Childrens Hospital of Philadelphia (CHOP) noted the specific requirements of this round of funding called for enrolling at least 2500 new participants who had not been previously involved with the hospitals Center for Applied Genomics (CAG), of which 75% must be African American.

The Center for Applied Genomics and the National Institutes of Health have had an excellent partnership within the eMERGE Network, and we are thrilled to continue to build upon the valuable work that we have been able to achieve so far with particular emphasis on resolving diseases in diverse patient populations and minority groups, Hakon Hakonarson, MD, PhD, director of the CAG at CHOP and principal investigator of the program, said in a statement. The primary goals of this program are to identify disease risks faced by patients and their families and to determine the most appropriate actions we can take to improve health outcomes. The program specifically focuses on African American children and their families, who will constitute 75% of participants.

Polygenic risk scores, which evaluate disease risk based on DNA variants, have previously been based almost entirely on patients who had European ancestry. Investigators have seen a need to incorporate data from patients from non-European ancestry into risk scores, as well as those who have clinical and lifestyle characteristics seen in the real world, such as higher body mass index (BMI), alcohol use, elevated blood glucose levels, and other factors that affect a persons risk level.

The eMERGE Network, launched in 2007, first collected electronic health record data to address this problem. The sites that will proactively collect data over the next 5 years will add new data to incorporate into risk calculations.

The goal is to develop protocols to estimate risk for common, complex diseases, such as coronary heart disease, diabetes, or Alzheimers disease, and incorporate health management recommendations for clinicians into the EHR using the Fast Healthcare Interoperability ResourceStandard, which spells out how health information is to be shared electronically.

Continue reading here:
NIH Funds Research to Understand How Genomics of Diverse Populations Affect Clinical Care - AJMC.com Managed Markets Network

Visit the News Hub

Radiologist also will lead clinical services

Radiologist Debbie Lee Bennett, MD, has been named chief of the breast imaging section at Washington University School of Medicine in St. Louis.

After a national search, noted radiologist Debbie Lee Bennett, MD, has been named chief of breast imaging forMallinckrodt Institute of Radiology(MIR) at Washington University School of Medicine in St. Louis.

Bennett will oversee screening and diagnostic mammography services offered throughSiteman Cancer CenteratBarnes-Jewish Hospitaland Washington University School of Medicine, including at the Joanne Knight Breast Health Center.

Bennett comes to the university from Saint Louis University School of Medicine, where she had served on the faculty since 2014, most recently as an associate professor. There, she established the breast imaging section and began serving as its chief in 2015.

We are very excited that someone with Dr. Bennetts proven leadership and experience is joining our breast imaging faculty, said Richard L. Wahl, MD, the Elizabeth Mallinckrodt Professor of Radiology, head of the radiology department at the School of Medicine and director of MIR. She also is a welcome addition to our team of clinical experts, whose skill and experience make a difference in the lives of our patients.

Bennett serves on several committees of professional and academic organizations, including the American College of Radiology, Society of Breast Imaging, American Board of Radiology and Radiological Society of North America. She also is engaged in outreach and education, and has mentored many residents who have gone on to pursue careers in breast imaging.

After an internship in internal medicine at Vanderbilt University Medical Center, she completed a residency in diagnostic radiology and a fellowship in breast imaging, both at Massachusetts General Hospital.

She earned her medical degree from Harvard Medical School and bachelors degree from Princeton University, graduating magna cum laude from both institutions.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff ofBarnes-JewishandSt. Louis Childrenshospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked toBJC HealthCare.

Siteman Cancer Center, ranked among the top cancer treatment centers by U.S. News & World Report, also is one of only a few cancer centers to receive the highest rating of the National Cancer Institute (NCI) exceptional. Comprising the cancer research, prevention and treatment programs ofBarnes-Jewish HospitalandWashington University School of Medicinein St. Louis, Siteman treats adults at six locations and partners withSt. Louis Childrens Hospitalin the treatment of pediatric patients. Siteman is Missouris only NCI-designated Comprehensive Cancer Center and the states only member of the National Comprehensive Cancer Network. Through theSiteman Cancer Network, Siteman Cancer Center works with regional medical centers to improve the health and well-being of people and communities by expanding access to cancer prevention and control strategies, clinical studies and genomic and genetic testing, all aimed at reducing the burden of cancer.

See more here:
Bennett named chief of breast imaging section - Washington University School of Medicine in St. Louis

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Abby H. Bronson to the newly created position of Vice President, Patient Advocacy and External Innovation. Ms. Bronson will be responsible for leading patient advocacy and building key external relationships with the muscular dystrophy community with the goal of bringing patient insights into drug development. This comes at an important time as Edgewise prepares EDG-5506, the companys lead product candidate, for clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD). Ms. Bronson brings a wealth of experience in the rare disease space, most recently serving as Senior Vice President of Research Strategy at Parent Project Muscular Dystrophy (PPMD), the largest patient centered advocacy organization devoted to finding a cure for Duchenne.

We are pleased to have Abby join our company as we advance our muscular dystrophy program and prepare EDG-5506 for clinical development, said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics. Having a strong patient advocacy perspective and voice in the DMD community is integral to executing against our vision of creating novel drugs that will transform the lives of patients living with severe musculoskeletal diseases. Abby brings an extensive patient advocacy background and we are fortunate to have someone with her knowledge and passion for the patient community join our team.

Im excited to join the dedicated team at Edgewise and to support the advancement of EDG-5506, a potentially transformative product candidate in DMD, through meaningful engagement with the patient and scientific communities, said Ms. Bronson.

Ms. Bronson is a leader within the rare disease space and over her career has managed critical alliances and partnerships with academia, biopharmaceutical companies, National Institutes of Health (NIH)/federal programs, patient groups and other stakeholders. Most recently she worked at PPMD as Senior Vice President of Research Strategy where she led the Research Portfolio and built strong relationships with Duchenne academic and clinical researchers, industry and regulators to help incorporate the patient voice and improve drug development success in DMD. Prior to this, Ms. Bronson was at the NIHs Center for Advancing Translational Sciences, Division of Clinical Innovation where she was Director of Operations for the Clinical and Translational Science Awards Program. Additionally, Ms. Bronson held positions at Children's National Medical Center, where she managed the global development and execution of key translational and drug development initiatives in select rare diseases, focusing on Duchenne at the Research Center for Genetic Medicine; MedImmune (acquired by Astra-Zeneca), where she led marketing initiatives for Synagis (palivizumab) for RSV disease; Medtronic where she managed global product marketing for select medical devices; and Ciba-Geneva Pharmaceuticals (acquired by Novartis) where she was responsible for managing relationships with major managed care organizations and led sales and marketing initiatives for their cardiovascular franchise. Ms. Bronson received her M.B.A from The Wharton School, University of Pennsylvania and B.A. degree from the University of Vermont.

About Muscular Dystrophy

Muscular dystrophies are a group of genetic disorders associated with defects in the critical muscle-associated structural protein dystrophin or the sarcomere complex and are characterized by progressive muscle degeneration and weakness. In individuals with neuromuscular conditions such as Duchenne muscular dystrophy, muscle contractions lead to continued rounds of muscle breakdown that the body struggles to repair. Eventually, as patients age, fibrosis and fatty tissue accumulate in the muscle portending a steep decline in physical function that ends with mortality. There remains an unmet need for treatments that reduce muscle breakdown in patients with neuromuscular conditions. Arresting this amplified muscle response will have a dramatic effect on disease progression.

About Edgewise Therapeutics

Edgewise Therapeutics, founded in 2017 by Alan Russell, Ph.D., Peter Thompson, M.D. (Orbimed Advisors) and Badreddin Edris, Ph.D., (Springworks Inc.), is pioneering the development of first-in-class medicines for the treatment of high morbidity musculoskeletal diseases. Skeletal muscle is the largest organ system in the human body, regulating both force production to enable muscle contraction, locomotion, and postural maintenance and the metabolism of glucose, fatty and amino acids. By modulating these processes in skeletal muscle, we create therapeutic agents that will reduce muscle damage, normalize muscle function, decrease mortality and profoundly benefit our patients quality of life. To learn more, go to: http://www.edgewisetx.com

Here is the original post:
Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation - Business Wire